Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


06.06.2022

1 Blood
1 BMC Cancer
1 Br J Cancer
1 Br J Haematol
1 Haematologica
6 Leuk Lymphoma
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Blood

  1. KAMDAR M
    A cauldron of choices.
    Blood. 2022;139:3103-3104.
    PubMed        


    BMC Cancer

  2. CHEN H, Zhong Q, Zhou Y, Qin Y, et al
    Enhancement of the International prognostic index with beta2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    BMC Cancer. 2022;22:583.
    PubMed         Abstract available


    Br J Cancer

  3. NOBLE RA, Thomas H, Zhao Y, Herendi L, et al
    Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01848.
    PubMed         Abstract available


    Br J Haematol

  4. STRUSSMANN T, Glatzki F, Engelhardt M, Mertelsmann R, et al
    Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.
    Br J Haematol. 2022 May 27. doi: 10.1111/bjh.18280.
    PubMed        


    Haematologica

  5. ROSSI C, Andre M, Dupuis J, Morschhauser F, et al
    High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.
    Haematologica. 2022 May 31. doi: 10.3324/haematol.2021.280004.
    PubMed         Abstract available


    Leuk Lymphoma

  6. BERGER T, Geiger KR, Yeshurun M, Gafter-Gvili A, et al
    Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study.
    Leuk Lymphoma. 2022 May 28:1-8. doi: 10.1080/10428194.2022.2081325.
    PubMed         Abstract available

  7. TARIQ H
    Classic Hodgkin lymphoma cloaked in an intense sarcoid-like reaction.
    Leuk Lymphoma. 2022 May 27:1-4. doi: 10.1080/10428194.2022.2081848.
    PubMed        

  8. ARULOGUN SO, Abbasi MA, Pomplun S, O'Neill AT, et al
    Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenstrom Macroglobulinaemia.
    Leuk Lymphoma. 2022;63:1496-1499.
    PubMed        

  9. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    PubMed         Abstract available

  10. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    PubMed         Abstract available

  11. GE J, Xia Y, Sun Z, Zhang L, et al
    Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
    Leuk Lymphoma. 2022;63:1369-1374.
    PubMed         Abstract available


    PLoS One

  12. TSUTSUE S, Makita S, Yi J, Crawford B, et al
    Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.
    PLoS One. 2022;17:e0269169.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: